Treating (Recurrent) Vulvovaginal Candidiasis with Medical-Grade Honey-Concepts and Practical Considerations

S.J.J.M. van Riel, C.M.J.G. Lardenoije, G.J. Oudhuis, N.A.J. Cremers*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

3 Citations (Web of Science)

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is a relapsing vaginal fungal infection caused by Candida species. The prevalence varies among age populations and can be as high as 9%. Treatment options are limited, and in 57% of the cases, relapses occur within six months after fluconazole maintenance therapy, which is the current standard of care. The pathogenesis of RVVC is multifactorial, and recent studies have demonstrated that the vaginal microenvironment and activity of the immune system have a strong influence on the disease. Medical-grade honey (MGH) has protective, antimicrobial, and immunomodulatory activity and forms a putative alternative treatment. Clinical trials have demonstrated that honey can benefit the treatment of bacterial and Candida-mediated vaginal infections. We postulate that MGH will actively fight ongoing infections; eradicate biofilms; and modulate the vaginal microenvironment by its anti-inflammatory, antioxidative, and immunomodulatory properties, and subsequently may decrease the number of relapses when compared to fluconazole. The MGH formulation L-Mesitran Soft has stronger antimicrobial activity against various Candida species than its raw honey. In advance of a planned randomized controlled clinical trial, we present the setup of a study comparing L-Mesitran Soft with fluconazole and its practical considerations.
Original languageEnglish
Article number664
Number of pages18
JournalJournal of Fungi
Volume7
Issue number8
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • recurrent vulvovaginal candidiasis
  • medical-grade honey
  • fluconazole
  • alternative treatment
  • micro-environment modulation
  • IN-VITRO SUSCEPTIBILITY
  • ALBICANS BIOFILMS
  • FLUCONAZOLE RESISTANCE
  • ANTIFUNGAL ACTIVITY
  • ANTIBACTERIAL
  • MANAGEMENT
  • CLOTRIMAZOLE
  • MECHANISMS
  • VIRULENCE
  • VAGINITIS

Cite this